Cochrane · systematic review · CD004429
Immunoglobulin for multifocal motor neuropathy
Keddie, S, Eftimov, F, van den Berg, LH, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
15
current version
GRADE rated
8
No studies
7
Included studies
NR
No studies 7 · 46.7%Ungraded 0 · 0%Very low 3 · 20%Low 3 · 20%Moderate 2 · 13.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
IVIg compared to placebo for multifocal motor neuropathy
Population: people with multifocal motor neuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Induction IVIg vs placebo | no estimate extracted | NR | No studies |
Proportion of participants with an improvement in disability scale used in the original study IVIg vs placebo | RR 3 [0.89, 10.12] | 18 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Proportion of participants with an improvement of muscle strength IVIg vs placebo | RR 11 [2.86, 42.25] | 27 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Proportion of participants with an improvement in disability at 12 months or later IVIg vs placebo | no estimate extracted | NR | No studies |
Proportion of participants in which at least 1 conduction block resolved after therapy IVIg vs placebo | RR 7 [0.95, 51.7] | 28 participants | Low Downgraded: risk of bias, imprecision |
Maintenance IVIg vs placebo | no estimate extracted | NR | No studies |
Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal, as determined and defined by study authors IVIg vs placebo | RR 2.43 [1.13, 5.24] | 42 participants | Moderate Downgraded: risk of bias, imprecision |
Proportion of IVIg‐treated participants with a decrease in muscle strength during controlled IVIg withdrawal IVIg vs placebo | RR 0.2 [0.07, 0.54] | 42 participants | Moderate Downgraded: risk of bias, imprecision |
Proportion of participants with side effects attributable to treatment IVIg vs placebo | RR 10.33 [2.15, 49.77] | 21 participants | Very low Downgraded: risk of bias, imprecision |
IVIg compared to SCIg for multifocal motor neuropathy
Population: people with multifocal motor neuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Induction IVIg vs SCIg | no estimate extracted | NR | No studies |
Maintenance IVIg vs SCIg | no estimate extracted | NR | No studies |
Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal IVIg vs SCIg | no estimate extracted | NR | No studies |
Change in mean muscle strength in participants on IVIg treatment at study entry IVIg vs SCIg | no estimate extracted | 9 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events IVIg vs SCIg | no estimate extracted | NR | No studies |
Proportion of participants with side effects attributable to treatment IVIg vs SCIg | RR 0.5 [0.18, 1.4] | 9 participants | Very low Downgraded: risk of bias, imprecision |